Mixed protocols: Multiple ratios of FSH and LH bioactivity using highly purified, human-derived FSH (BRAVELLE) and highly purified hMG (MENOPUR) are unaltered by mixing together in the same syringe

Reproductive Biology and Endocrinology

Volumn 3, Issue , 2005, Pages

  Scobey, M Joseph ^a   Raike, Elisabeth ^b   Marshall, Dennis C ^a  

^a Ferring Pharmaceuticals Inc   (United States)

^b Qualtech Laboratories Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FOLLITROPIN; HUMAN MENOPAUSAL GONADOTROPIN; LUTEINIZING HORMONE; SODIUM CHLORIDE; UROFOLLITROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG MIXTURE; FEMALE; HORMONE ACTION; MALE; NONHUMAN; OVULATION INDUCTION; RAT; STATISTICAL SIGNIFICANCE; SYRINGE; ANIMAL; BIOASSAY; BIOAVAILABILITY; DRUG COMBINATION; METHODOLOGY; SPRAGUE DAWLEY RAT; WISTAR RAT;

ANIMALIA;

ANIMALS; BIOLOGICAL ASSAY; BIOLOGICAL AVAILABILITY; DRUG COMBINATIONS; FEMALE; MALE; MENOTROPINS; OVULATION INDUCTION; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; SYRINGES; UROFOLLITROPIN;

EID: 27944494814     PISSN: 14777827     EISSN: 14777827     Source Type: Journal    
DOI: 10.1186/1477-7827-3-61     Document Type: Article

References (15)

1. Greep RO, Van Dyke HB, Chan BF: Gonadotropins of the swine pituitary: various biological effects of purified thylakentrin (FSH) and pure metakentrin (ICSH). Endocrinolology 1942, 30:635-649.
2. Gemzell CA, Diczfalusy E, Tillinger KG: Clinical effects of human pituitary follicle stimulating hormone (FSH). J Clin Endocrinol Metab 1958, 18:1333-1348.
3. March CM: Human menopausal gonadotropins. In Infertility and reproductive medicine. Clinics of North America Vol. 1: Edited by Diamond MP, De Cherney AH. Philadelphia: WB Saunders; 1990:59-77.
4. Donini P, Puzzuoli D, D'Alessio I, Lunenfeld B, Eshkol A, Parlow AF: Purification and separation of follicle stimulating hormone (FSH) and luteinizing hormone (LH) from human postmenopausal gonadotropin (HMG). II. Preparation of biological apparently pure FSH by selective binding of the LH with an anti-hCG serum and subsequent chromatography. Acta Endocrinol (Copenh) 1966, 52:186-198.
5. Homburg R, Armar NA, Eshel A, Adams J, Jacobs HS: Influence of serum luteinizing hormone concentrations on ovulation, conception, and early pregnancy loss in polycystic ovary syndrome. BMJ 1988, 297:1024-1026.
6. Lambert A, Rodgers M, Mitchell R, Wood AM, Wardle C, Hilton B, Robertson WR: In-vitro biopotency and glycoform distribution of recombinant human follicle stimulating hormone (Org 32489), Metrodin and Metrodin-HP. Hum Reprod 1995, 10:1928-1935.
7. Marshall DC, Raike E, De Silva M, Nardi RV: Mixed protocol same syringe combination of gonadotropins: compatibility of Ferring's new highly-purified, human-derived FSH (Bravelle®) and hMG (Repronex). Today's Therapeutic Trends 2001, 19:213-224.
8. The United States Pharmacopeia, 26th rev., and The National Formulary, 21st ed. Rockville: The United States Pharmacopeial Convention. 2003:2033-2045.
9. Dickey RP, Nichols JE, Steinkampf MP, Gocial B, Thornton M, Webster BW, Bello SM, Crain J, Marshall DC: Highly purified human-derived follicle-stimulating hormone (Bravelle®) has equivalent efficacy to follitropin-beta (Follistim®) in infertile women undergoing in vitro fertilization. Reprod Biol Endocrinol 2003,1(1):63
10. Gocial B, Keye WR, Fein SH, Nardi RV: Subcutaneously administered Repronex in female patients undergoing in vitro fertilization is as effective and well tolerated as intramuscular menotropin treatment. Fert Ster 2000, 74:73-79.
11. Horsman G, Talbot JA, McLoughlin JD, Lambert A, Robertson WR: A biological, immunological and physico-chemical comparison of the current clinical batches of the recombinant FSH preparations Gonal-F and Puregon. Hum Reprod 2000, 15:1898-1902.
12. Corbo DC, Suddith RL, Sharma B, Naso RB: Stability, potency, and preservative effectiveness of epoetin alfa after addition of a bacteriostatic diluent. Am J Hosp Pharm 1992, 49:1455-1458.
13. Law SL, Shih CL: Adsorption of calcitonin to glass. Drug Dev Ind Pharm 1999, 25:253-256.
14. Amiji M, Park K: Prevention of protein adsorption and platelet adhesion on surfaces by PEO/PPO/PEO triblock copolymers. Biomaterials 1992, 13:682-692.
15. Keye WR, Webster B, Dickey R, Somkuti S, Crain J, Scobey MJ: Subcutaneously Administered Menopur®, A New Highly Purified Human Menopausal Gonadotropin Causes Significantly Fewer Injection Site Reactions Than Repronex® in Subjects Undergoing In Vitro Fertilization. Reprod Biol Endocrin, in press.